CABG Clinical Trial
— EMPOAFOfficial title:
Evaluating the Role of EMpagliflozin on the Rate of Post-Operative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Double-blind Placebo-controlled Randomized Clinical Trial
This is an interventional, double-blind, placebo controlled, multicenter, randomized clinical trial with allocation sequence concealment and blinded endpoint adjudication. The goal of present study is to investigate if periprocedural administration of 10 mg once daily empagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2I), can reduce the incidence of post-operative atrial fibrillation and/or atrial flutter in patients with chronic coronary syndrome scheduled for isolated CABG. This trial will be conducted in two referral teaching cardiology hospitals in Tehran. 492 adult patients who are scheduled for elective isolated coronary artery bypass graft (CABG) surgery will be randomly assigned to one of the groups of intervention (empagliflozin 10 mg daily) or placebo starting 3 days before surgery until discharge.
Status | Recruiting |
Enrollment | 492 |
Est. completion date | December 30, 2024 |
Est. primary completion date | December 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion criteria - Adult patients (=18 years) who are candidates for isolated CABG - Patients who provided written informed consent and are willing to participate in the study Exclusion criteria - History of type ? or ? diabetes mellitus - History of ketoacidosis - History of atrial fibrillation or flutter - History of recurrent UTI - SGLT2I or any other oral hypoglycemic medications used due to other indications - Patients with acute kidney injury (45) - Severe hepatic disease (Child-Pugh score C) - Patients with Estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73m2 - Patients who are candidates for emergent CABG - Patients with unstable hemodynamic state - Patients with positive urine culture, urinary symptoms (frequency, dysuria, hesitancy), and asymptomatic bacteriuria - Patients who are enrolled in other clinical trials - Patients with a history of drug-sensitive reactions to SGLT2I - Pregnancy or lactation |
Country | Name | City | State |
---|---|---|---|
Iran, Islamic Republic of | Rajaie Cardiovascular Medical & Research Center | Tehran | |
Iran, Islamic Republic of | Tehran Heart Center | Tehran |
Lead Sponsor | Collaborator |
---|---|
Rajaie Cardiovascular Medical and Research Center | Tehran Heart Center |
Iran, Islamic Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of POAF | Incidence of new-onset postoperative atrial fibrillation (AF) and/or atrial flutter (AFL), defined as any adjudicated documented AF or AFL of at least 30 seconds duration and documented by Holter ECG monitoring during the admission time in the ICU (at least 72 hours and maximum 30 days). | From CABG until discharge from the intensive care unit (at least 72 hours and maximum 30 days) | |
Secondary | Composite Incidence of all arrhythmias leading to hemodynamic instability | Defined as any adjudicated documented tachy- or bradyarrhythmia of at least 30 seconds duration and documented by rhythm strips or 12-lead ECG leading to hemodynamic instability during the admission time. Ventricular tachycardia (VT) of at least 30 seconds duration and documented by rhythm strip or 12-lead ECG.
Ventricular fibrillation (VF) of at least 30 seconds duration and documented by rhythm strip or 12-lead ECG |
From CABG until discharge from the hospital (maximum 30 days). | |
Secondary | Incidence of post-operative acute kidney injury | Defined as the presence of either the increase in serum creatinine by = 0.3 mg/dl (= 26.5 µmol/l) within 48 hours; or an increase in serum creatinine to = 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or urine volume < 0.5 ml/kg/h for 6 hours based on the KDIGO definition of AKI | From CABG until 7th post-operation day. | |
Secondary | Need for vasopressor/inotrope | Defined as cumulative vasopressor index and the amount of average daily inotrope dose during the admission time in the ICU | From CABG until discharge from the intensive care unit (maximum 30 days). | |
Secondary | Duration of hospitalization | Defined as number of days a patient stay at the hospital | From CABG until discharge from the hospital. | |
Secondary | All-cause mortality | Defined as adjudicated 30-day mortality, including cause-specific mortality: cardiac arrhythmic, cardiac non-arrhythmic, and non-cardiovascular. | From CABG until 30th post-operation day. | |
Secondary | Incidence of life-threatening infections | Defined as any adjudicated laboratory and clinically confirmed systemic infection that necessitate the administration of parenteral broad spectrum antibiotics | From CABG until discharge (maximum 30 days). | |
Secondary | Incidence of genitourinary tract infections | Defined as any adjudicated laboratory and clinically confirmed genitourinary tract infection including cystitis, pyelonephritis, prostatitis, urethritis, and vaginitis | From CABG until discharge from the hospital (maximum 30 days). | |
Secondary | Incidence of hypoglycemia | Defined as serum blood sugar = 70 mg/dL (= 3.9 mmol/L) | From CABG until discharge from the hospital (maximum 30 days). | |
Secondary | Incidence of ketoacidosis | Defined as blood pH = 7.3, serum bicarbonate less than 15 mEq/l, and presence of ketonemia or ketonuria | From CABG until discharge from the hospital (maximum 30 days). | |
Secondary | Incidence of clinically-diagnosed ischemic stroke | Defined as the sudden loss of blood circulation to an area of the brain that has been confirmed with appropriate diagnostic imaging (Brain CT/MRI) | From CABG until 30th post-operation day. | |
Secondary | Composite incidence of arterial and venous thrombosis | Defined as adjudicated arterial thrombosis (including Type I MI and peripheral arterial thrombosis) and venous thrombosis (including DVT and PE) confirmed with appropriate diagnostic tools | From CABG until 30th post-operation day. | |
Secondary | Need for renal replacement therapy | defined as treatment with any forms of dialysis (hemodialysis, hemodiafiltration, and peritoneal dialysis), hemofiltration, and renal transplantation | From CABG until discharge from the intensive care unit (maximum 30 days). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01956708 -
Transfer of Cardioprotection During RIPC
|
N/A | |
Completed |
NCT01928745 -
Experimental Determination of Atot en Ka in the Critically Ill
|
N/A | |
Active, not recruiting |
NCT00966654 -
Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery
|
Phase 2 | |
Completed |
NCT01282671 -
Effects of Deep Breathing Exercises Two Months After Cardiac Surgery
|
Phase 2 | |
Completed |
NCT00524901 -
Study of the Use of a Single Dose of Erythropoietin to Treat Acute Myocardial Ischemia
|
Phase 2 | |
Completed |
NCT03050489 -
Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG
|
||
Completed |
NCT00269243 -
Management With Accupril Post Bypass Graft
|
Phase 4 | |
Recruiting |
NCT03139929 -
Measurement of MSFP and Stressed Volume With CardioQ+®
|
||
Active, not recruiting |
NCT03424941 -
The TransCatheter Valve and Vessels Trial
|
N/A | |
Completed |
NCT06317363 -
Effects of Acapella VS CHEST Physiotherapy in Post-Operative CABG Patients
|
N/A | |
Completed |
NCT05023083 -
Cross Cultural Adaptation of Functional Status Questionnaire in Urdu Language in CABG Patients
|
||
Completed |
NCT03800264 -
Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery
|
Phase 4 | |
Completed |
NCT05285865 -
Scapular Mobilization on Inspiratory Capacity of Post-CABG Patients
|
N/A | |
Not yet recruiting |
NCT06173609 -
Long LIMA Patch on Left Anterior Descending Coronary Artery in CABG
|
||
Not yet recruiting |
NCT06238011 -
Dexmedetomidine vs Control on Attenuation Hemodynamic Response to Noxious Stimuli in CABG Surgical Patients
|
N/A | |
Active, not recruiting |
NCT06127147 -
High-intensity Inspiratory Muscle Training as a Pre-cardiac Rehabilitation in Heart Disease
|
N/A | |
Recruiting |
NCT06029556 -
Effects of Early Mobility Protocols in Cardiac ICU
|
N/A | |
Enrolling by invitation |
NCT01205620 -
IRB-HSR# 15084 A Prospective, Unblinded, Controlled Study to Evaluate the Effect of the ITPR in Patients Undergoing OPCAB Surgery
|
Phase 2 |